• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Defiance Launches RKLX and HIMZ: 2X Leveraged ETFs for Rocket Lab and Hims & Hers

    3/13/25 1:00:00 AM ET
    $HIMS
    $RKLB
    Medical/Nursing Services
    Health Care
    Military/Government/Technical
    Industrials
    Get the next $HIMS alert in real time by email

    MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs introduces RKLX and HIMZ, two 2X leveraged single-stock ETFs designed to provide amplified exposure to Rocket Lab USA, Inc. (NASDAQ:RKLB) and Hims & Hers Health Inc. (NYSE:HIMS). These ETFs offer traders a way to seek enhanced returns on Rocket Lab and Hims & Hers without requiring a margin account.

    • RKLX, the Defiance Daily Target 2X Long RKLB ETF, seeks daily investment results that correspond to twice (200%) the daily percentage change of Rocket Lab, a company at the forefront of satellite launches, space exploration, and advanced aerospace systems.
    • HIMZ, the Defiance Daily Target 2X Long HIMS ETF, seeks daily investment results that correspond to twice (200%) the daily return of Hims & Hers, a company pioneering telehealth and direct-to-consumer healthcare solutions.

    "RKLX and HIMZ offer compelling opportunities for investors seeking amplified exposure to Rocket Lab and Hims & Hers, two companies driving innovation in their respective industries," said Sylvia Jablonski, CEO of Defiance ETFs. "With increasing demand for satellite technology and digital healthcare solutions, Rocket Lab and Hims & Hers continue to play key roles in shaping the future of space exploration and telehealth."

    For more information, visit DefianceETFs.com

    These Funds are not intended to be used by, and are not appropriate for, investors who do not intend to actively monitor and manage their portfolios. The Funds pursue a daily leveraged investment objective, making them riskier than alternatives that do not use leverage, as they magnify the performance of their respective underlying securities. These Funds are not suitable for all investors. They are designed for knowledgeable investors who understand the potential consequences of seeking daily leveraged (2X) investment results, recognize the risks associated with the use of leverage, and are willing to frequently monitor their portfolios. Over periods longer than a single day, the Funds may lose value even if their underlying securities increase in performance, and they will lose value if the underlying securities remain flat. An investor could lose the full principal value of their investment within a single day.

    An investment in RKLX is not an investment in Rocket Lab USA, Inc. An investment in HIMZ is not an investment in Hims & Hers Health Inc.

    About Defiance ETFs

    Founded in 2018, Defiance is at the forefront of ETF innovation. Defiance is a leading ETF issuer specializing in thematic, income, and leveraged ETFs.

    Our first-mover leveraged single-stock ETFs empower investors to take amplified positions in high-growth companies, providing precise leverage exposure without the need to open a margin account.

    IMPORTANT DISCLOSURES

    Defiance ETFs LLC is the ETF sponsor. The Fund's investment adviser is Tidal Investments, LLC ("Tidal" or the "Adviser").

    The Funds' investment objectives, risks, charges, and expenses must be considered carefully before investing. The prospectus and summary prospectus contain this and other important information about the investment company. Please read carefully before investing. A hard copy of the prospectuses can be requested by calling 833.333.9383.

    Investing involves risk. Principal loss is possible. As an ETF, the funds' may trade at a premium or discount to NAV. Shares of any ETF are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. A portfolio concentrated in a single industry or country, may be subject to a higher degree of risk.

    RKLB and HIMS Risks: The Fund invests in swap contracts and options that are based on the share price of HIMS. This subjects the Fund to certain of the same risks as if it owned shares of HIMS even though it does not.

    Indirect Investment Risk. RKLB and HIMS are not affiliated with the Trust, the Fund, or the Adviser, or their respective affiliates and are not involved with this offering in any way and have no obligation to consider your Shares in taking any corporate actions that might affect the value of Shares.

    Trading Risk. The trading price of the fund may be subject to volatility and could experience wide fluctuations due to various factors. Short sellers may also play a significant role in trading RKLB and HIMS potentially affecting the supply and demand dynamics and contributing to market price volatility. Public perception and external factors beyond the company's control may influence RKLB's and HIMS's stock price disproportionately.

    Performance Risk. RKLB and HIMS may fail to meet publicly announced guidelines or other expectations about its business, which could cause the price of RKLB and HIMS to decline.

    RKLB Aerospace & Defense Industry Risks. Companies in the aerospace and defense industry are subject to risks stemming from their reliance on government budgets and spending priorities, which can fluctuate due to political and economic pressures. The aerospace and defense industry is also affected by geopolitical tensions, trade policies, and regulatory changes that can impact market access and operational efficiency. Aerospace and defense companies typically rely on complex supply chains for specialized components and materials. Additionally, technological advancements are critical for maintaining competitiveness in this sector, but the high cost and uncertain outcomes of research and development efforts may pose financial risks. Companies in this industry face heightened cybersecurity risks due to the sensitive nature of their technologies, and breaches can lead to operational disruptions, reputational damage, and regulatory scrutiny. 

    RKLB Business Risks. RKLB has experienced rapid growth, with its employee base and operations expanding substantially in recent years, placing considerable demands on its management, operational infrastructure, and financial resources. Continued growth is dependent on RKLB's ability to scale its revenue, improve operational efficiencies, and maintain profitability while effectively managing its increasingly complex organizational structure. Additionally, interruptions from information technology failures, cybersecurity breaches, or other infrastructure issues could disrupt operations. RKLB's ability to comply with applicable regulations and adapt to changes in the industry also presents ongoing risks.

    HIMS Healthcare Providers & Services Industry Risks. The healthcare providers and services industry can be significantly affected by changing economic conditions, evolving patient demographics, and fluctuations in demand for healthcare services. Changes in healthcare regulations and policies, including those related to insurance coverage and reimbursement, can materially impact the industry. Additionally, the industry faces risks related to litigation, operational disruptions, and evolving technologies that may alter traditional service delivery models.

    HIMS Business Risks. HIMS operates in highly competitive markets, facing challenges from established healthcare providers, retailers, pharmaceutical companies, and technology firms, which may affect its competitive position. Additionally, the success of HIMS is heavily reliant on its brand reputation, relationships with healthcare providers and medical groups, and compliance with complex healthcare and pharmacy regulations. Security breaches, data loss, legal proceedings, or regulatory changes could harm its operations and reputation.

    RKLX and HIMZ Fund Risks 

    Leverage Risk. The Fund obtains investment exposure in excess of its net assets by utilizing leverage and may lose more money in market conditions that are adverse to its investment objective than a fund that does not utilize leverage. An investment in the Fund is exposed to the risk that a decline in the daily performance of the Underlying Security will be magnified.

    High Portfolio Turnover Risk. Daily rebalancing of the Fund's holdings pursuant to its daily investment objective causes a much greater number of portfolio transactions when compared to most ETFs.

    Liquidity Risk. Some securities held by the Fund may be difficult to sell or be illiquid, particularly during times of market turmoil. Markets for securities or financial instruments could be disrupted by a number of events, including, but not limited to, an economic crisis, natural disasters, epidemics/pandemics, new legislation or regulatory changes inside or outside the United States.

    Derivatives Risk. The Fund's investments in derivatives may pose risks in addition to, and greater than, those associated with directly investing in securities or other ordinary investments, including risk related to the market, leverage, imperfect daily correlations with underlying investments or the Fund's other portfolio holdings, higher price volatility, lack of availability, counterparty risk, liquidity, valuation and legal restrictions.

    Compounding and Market Volatility Risk. The Fund has a daily leveraged investment objective and the Fund's performance for periods greater than a trading day will be the result of each day's returns compounded over the period, which is very likely to differ from two times (200%) the Underlying Security's performance, before the Fund's management fee and other expenses.

    Fixed Income Securities Risk. When the Fund invests in fixed income securities, the value of your investment in the Fund will fluctuate with changes in interest rates. Typically, a rise in interest rates causes a decline in the value of fixed income securities owned by the Fund.

    Single Issuer Risk. Issuer-specific attributes may cause an investment in the Fund to be more volatile than a traditional pooled investment which diversifies risk of the market generally. The value of the Fund, which focuses on an individual security, may be more volatile than a traditional pooled investment or the market as a whole and may perform differently from the value of a traditional pooled investment or the market as a whole.

    New Fund Risk. The Fund is a recently organized management investment company with no operating history. As a result, prospective investors do not have a track record or history on which to base their investment decisions.

    Diversification does not ensure a profit nor protect against loss in a declining market.

    Brokerage Commissions may be charged on trades.

    Distributed by Foreside Fund Services, LLC

    Contact Information

    David Hanono

    [email protected]

    833.333.9383

    A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/25cf1c68-b060-42fa-b3cf-e1315eea5f0e



    Get the next $HIMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HIMS
    $RKLB

    CompanyDatePrice TargetRatingAnalyst
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$24.00Sell → Neutral
    Citigroup
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$23.00Underperform → Neutral
    BofA Securities
    Hims & Hers Health Inc.
    $HIMS
    3/9/2026$30.00Hold → Buy
    Needham
    Hims & Hers Health Inc.
    $HIMS
    2/24/2026Buy → Neutral
    BTIG Research
    Rocket Lab Corporation
    $RKLB
    1/16/2026$105.00Equal-Weight → Overweight
    Morgan Stanley
    Rocket Lab Corporation
    $RKLB
    1/15/2026Overweight → Sector Weight
    KeyBanc Capital Markets
    Hims & Hers Health Inc.
    $HIMS
    1/12/2026$33.00In-line
    Evercore ISI
    Hims & Hers Health Inc.
    $HIMS
    12/9/2025$48.00Overweight
    Barclays
    More analyst ratings

    $HIMS
    $RKLB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manuel Anja bought $132,260 worth of shares (5,000 units at $26.45) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    11/14/24 4:57:45 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Payne Christopher D bought $1,951,763 worth of shares (110,000 units at $17.74) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/22/24 4:16:26 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    $RKLB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hims & Hers Names Kathryn Beiser as Chief Communications Officer

    The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world's leading consumer health platform in its next phase of growth Hims & Hers Health, Inc. (NYSE:HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company's expansive vision for the

    3/10/26 8:08:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Introducing Hims & Hers Benefits, Unlocking Health & Wellness Discounts for Subscribers

    The program debuts with Prenuvo and Eight Sleep, providing discounts on advanced diagnostics and sleep technology Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced Hims & Hers Benefits, a new way for subscribers to access the best innovations in whole body health. This new initiative provides active subscribers access to discounts from health partners, all in one place, including whole body MRI scans from Prenuvo and adaptive bed systems from Eight Sleep. This is just the beginning of a larger benefits program that will make comprehensive, holistic care more accessible and affordable for subscribers. "True health doesn't happen in a vacuum.

    3/10/26 9:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Announces Strategic Shift for US Weight Loss Business

    Starting with a new collaboration with Novo Nordisk, the company announced plans to align its US and global strategies with a focus on an increasing variety of FDA-approved GLP-1s Hims & Hers Health, Inc. (NYSE:HIMS) today announced a collaboration with Novo Nordisk as part of a new strategy for weight loss care treatments involving GLP-1s, evolving its US offering to match the company's approach globally. In the US, the company now plans to provide GLP-1 customers with access to a broad assortment of FDA-approved medications and offer compounded semaglutide through the platform on a limited scale. By aligning its domestic and international models in weight loss, Hims & Hers will become t

    3/9/26 8:30:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    $RKLB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Saintil Merline sold $1,360,171 worth of shares (18,126 units at $75.04), decreasing direct ownership by 6% to 261,903 units (SEC Form 4)

    4 - Rocket Lab Corp (0001819994) (Issuer)

    3/9/26 8:06:01 PM ET
    $RKLB
    Military/Government/Technical
    Industrials

    Chief Financial Officer Spice Adam C. sold $4,366,349 worth of shares (62,744 units at $69.59), decreasing direct ownership by 5% to 1,296,824 units (SEC Form 4)

    4 - Rocket Lab Corp (0001819994) (Issuer)

    3/4/26 9:25:38 PM ET
    $RKLB
    Military/Government/Technical
    Industrials

    Chief Operations Officer Klein Frank sold $5,740,940 worth of shares (81,250 units at $70.66), decreasing direct ownership by 7% to 1,088,237 units (SEC Form 4)

    4 - Rocket Lab Corp (0001819994) (Issuer)

    3/4/26 9:25:21 PM ET
    $RKLB
    Military/Government/Technical
    Industrials

    $HIMS
    $RKLB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hims & Hers Health upgraded by Citigroup with a new price target

    Citigroup upgraded Hims & Hers Health from Sell to Neutral and set a new price target of $24.00

    3/10/26 8:37:35 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health upgraded by BofA Securities with a new price target

    BofA Securities upgraded Hims & Hers Health from Underperform to Neutral and set a new price target of $23.00

    3/10/26 8:37:14 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health upgraded by Needham with a new price target

    Needham upgraded Hims & Hers Health from Hold to Buy and set a new price target of $30.00

    3/9/26 11:28:34 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    $RKLB
    SEC Filings

    View All

    SEC Form 144 filed by Rocket Lab Corporation

    144 - Rocket Lab Corp (0001819994) (Subject)

    3/6/26 4:20:20 PM ET
    $RKLB
    Military/Government/Technical
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by Hims & Hers Health Inc.

    SCHEDULE 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    3/5/26 11:49:35 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 144 filed by Rocket Lab Corporation

    144 - Rocket Lab Corp (0001819994) (Subject)

    3/4/26 4:33:23 PM ET
    $RKLB
    Military/Government/Technical
    Industrials

    $HIMS
    $RKLB
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Names Kathryn Beiser as Chief Communications Officer

    The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world's leading consumer health platform in its next phase of growth Hims & Hers Health, Inc. (NYSE:HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company's expansive vision for the

    3/10/26 8:08:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

    Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company's ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structu

    2/19/26 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy

    Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor as the company's first Chief Policy Officer. In this new role, Autor will collaborate with other stakeholders, including consumers, telehealth platforms, providers, advocacy groups, medical associations, pharmaceutical companies, medtech innovators, policymakers, and regulators, with the goal of paving the way to the healthcare of the future - where the power of technology will be combined with the best of personalized care. She will lead the company's global public policy, regulatory, and government affairs functions. A former senior leader at the FDA, prosecutor f

    11/17/25 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    $RKLB
    Financials

    Live finance-specific insights

    View All

    Rocket Lab Establishes New Precision Machining Complex, Expands Manufacturing Footprint with Acquisition of Precision Components Ltd

    LONG BEACH, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rocket Lab Corporation (NASDAQ:RKLB), a global leader in launch and space systems, today announced the acquisition of Precision Components Limited (PCL) in Auckland, New Zealand, expanding Rocket Lab's high volume, precision manufacturing capabilities. The newly acquired facility will be established as the Auckland Machine Complex, dedicated to the production of high-tech, high-tolerance machined components and engineering service for the global aerospace industry. The new facility will play a pivotal role in the high-volume manufacturing of components for Rocket Lab's spacecraft customers, support the continued acceleration of Electro

    2/26/26 4:09:00 PM ET
    $RKLB
    Military/Government/Technical
    Industrials

    Rocket Lab Acquires Optical Support, Inc., Strengthening National Security Payload Capability

    LONG BEACH, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rocket Lab Corporation (NASDAQ:RKLB) ("Rocket Lab" or the "Company"), a global leader in launch services and space systems, today announced it has completed the acquisition of Optical Support, Inc. (OSI), a leader in the design, engineering, and manufacturing of custom, high-precision optical and optomechanical instruments. OSI's advanced lenses and optomechanical systems are critical enablers for national security and commercial satellites, and are key subsystems used in Rocket Lab Optical Systems' high-performance payloads for space protection, space domain awareness, missile warning, tracking and defense. OSI delivers end-to-end solu

    2/26/26 4:06:00 PM ET
    $RKLB
    Military/Government/Technical
    Industrials

    Rocket Lab Announces Fourth Quarter and Full Year 2025 Financial Results, Posts Record Quarterly Revenue of $180M, Record Annual Revenue of $602M, Delivering Annual Growth of 38% and Growing Backlog 73% Year-on-Year to $1.85B

    LONG BEACH, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rocket Lab Corporation (NASDAQ:RKLB) ("Rocket Lab", "the Company", "we," "us," or "our"), a global leader in launch services and space systems, today shared the financial results for fiscal fourth quarter and full year ended December 31, 2025. Rocket Lab founder and CEO, Sir Peter Beck, said: "2026 was a record-breaking year for Rocket Lab financially and operationally. We delivered record quarterly revenue of $180 million, which brought our full year revenue to a record $602 million, representing 38% growth year on year. We reached a new annual launch record, flying 21 missions across Electron and HASTE with a 100% success rate for th

    2/26/26 4:05:00 PM ET
    $RKLB
    Military/Government/Technical
    Industrials

    $HIMS
    $RKLB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Rocket Lab USA Inc.

    SC 13D/A - Rocket Lab USA, Inc. (0001819994) (Subject)

    12/5/24 9:49:25 PM ET
    $RKLB
    Military/Government/Technical
    Industrials

    Amendment: SEC Form SC 13D/A filed by Rocket Lab USA Inc.

    SC 13D/A - Rocket Lab USA, Inc. (0001819994) (Subject)

    12/3/24 9:39:57 PM ET
    $RKLB
    Military/Government/Technical
    Industrials

    Amendment: SEC Form SC 13G/A filed by Rocket Lab USA Inc.

    SC 13G/A - Rocket Lab USA, Inc. (0001819994) (Subject)

    11/12/24 4:45:55 PM ET
    $RKLB
    Military/Government/Technical
    Industrials